17,261 trials
Carcinoma, Renal Cell
Primary: Objective Response Rate (Percentage of Participants With Complete Response [CR] or Partial Response [PR]): Independent Review Committee Assessment — 50.0 percentage of…
Breast Cancer
Primary: Number of Participants With Objective Response (OR) — 8 participants
Pain
Primary: Pain Area Under the Curve 0-8h (AUC0-8h) — 355; 356; 129 mm*h
Hot Flashes
Primary: Percent Change in Frequency of Hot Flashes Over Time — -77.2; -51.8; -53.8; -67.0 Percent change from baseline
Metabolic Syndrome · Insulin Resistance
Primary: Adipose Tissue Capillary Sprout Formation — 143.5; 122.1 number of capillary sprouts
Infections, Papillomavirus
Primary: Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms — 46; 18; 19; 2 Participants
Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Response Rate (Complete Response (CR) or Partial Response (PR)) — 1 participants
Stress-related Changes in Inflammation
Primary: Serum ln(IL-6) — 0.054; 0.051 ln(pg/mL) — p=0.97
Allergic Conjunctivitis
Primary: Ocular Itching — 1.48; 1.84; 1.82; 1.93 Units on a Scale
Metastatic Colorectal Cancer
Primary: Progression-Free Survival (PFS) — 9.1; 8.7 Months — p=0.2309
Acute Myeloid Leukemia (AML) · Myelodysplastic Syndrome
Primary: Percentage of Participants With Objective Response (OR) — 0 Percentage of participants
Kidney Neoplasms
Primary: Percentage of Participants With Objective Response (OR) — 44.2 Percentage of participants
Esophageal Cancer
Primary: The Number of Patients With Complete or Partial Response Rate of Single Agent ZD1839 in a Patient Population With Recurrent or Metastatic Cancer of the Esophagus or…
Lung Neoplasms · Carcinoma, Non-small Cell Lung
Primary: Percentage of Participants With Objective Response (OR) — 9.4 Percentage of participants
Pharmacokinetics
Primary: Area Under the Curve Over Dosing Interval at Steady State (AUC12,ss) Following IV Administration — 22.39 μg*h/mL